Previstagetrade; GCC colorectal cancer staging test: A new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer

Molecular Diagnosis and Therapy

Volumn 13, Issue 1, 2009, Pages 11-14

  Carlson, Marilyn R ^a  

^a entreMeDica Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANYLATE CYCLASE; MESSENGER RNA; ENTEROTOXIN RECEPTOR; RECEPTOR;

ANALYTICAL EQUIPMENT; ARTICLE; CANCER STAGING; COLORECTAL CANCER; COST; HUMAN; LYMPH NODE METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE; SENSITIVITY AND SPECIFICITY; COLORECTAL TUMOR; DIAGNOSTIC PROCEDURE; ENZYMOLOGY; LYMPH NODE; METABOLISM; PATHOLOGY; REVIEW; TUMOR RECURRENCE;

COLORECTAL NEOPLASMS; GUANYLATE CYCLASE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, PEPTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 64349109688     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03256309     Document Type: Article

References (12)

1. National Cancer Institute of Canada. Canadian cancer statistics 2008. Toronto: National Cancer Institute of Canada, 2008 [online]. Available from URL: http://www.cancer.ca/Canada-wide/About+cancer/Cancer+statistics. aspx?sc-lang = en [Accessed 2009 Jan 22]
2. American Cancer Society. Cancer facts & figures. Atlanta (GA): American Cancer Society, 2008 [online]. Available from URL: http://www.cancer. org/ docroot/STT/STT-0.asp [Accessed 2009 Jan 22]
3. Iddings D, Ahmad A, Elashoff D, et al. The prognostic effect of micro- metastases in previously staged lymph node negative (NO) colorectal carcinoma: a meta-analysis. Ann Surg Oncol 2006; 11: 1386-92
4. Compton CC, Fielding P, Burgart LJ, et al. Prognostic factors in colorectal cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-94
5. National Comprehensive Cancer Network. NCCN clinical practice guide- lines in oncology™: colon cancer. V.I.2009 [online]. Available from URL: http://www.nccn.org/professionals/physician-gls/PDF/colon.pdf [Accessed 2009 Feb 10]
6. Gelman A, Desnoyers R, Cagir B, et al. Colorectal cancer staging and adjuvant chemptherapy. Expert Opin Pharmacother 2000; 1: 737-55
7. Bostick PJ, Chatterjee S, Chi DD, et al. Limitations of specific reverse- transcriptase polymerase chain reaction markers in the detection of meta-stases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998; 16:2632-40
8. Nicastri D, Doucette J, Godfrey T, et al. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J Mol Diagn 2007; 9 (5): 563-71
9. Birbe R, Palazzo JP, Walters R, et al. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia and adenocarcinoma of the gastrointestinal tract. Hum Pathol 2005; 36: 170-9
10. Schulz S, Hyslop T, Haaf J, et al. A validated quantitative assay to detect occult micrometastases by reverse transcriptase polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res 2006; 12: 4545-52
11. Frick GS, Pitari GM, Weinberg DS, et al. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn 2005; 5: 701-13
12. Cagir B, Gelmann A, Parks J, et al. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med 1999; 131: 805-12